We are so excited to report the adoption of the landmark resolution on Skin Diseases at the 78th World Health Assembly. Your support has been invaluable in elevating the commitment to skin health worldwide.
Oncolytic therapy, introduced a decade ago, is gaining momentum as a promising treatment for melanoma. Advanced practice providers play a key role in implementing therapies like intralesional injections and require education, skill development, and credentialing support as they adopt oncolytic virotherapy. This APSHO-endorsed curriculum offers didactic content, instructional videos, and future hands-on training opportunities to support the expanded use of oncolytic therapies in clinical practice.
Oncolytic therapy was first introduced in the field of oncology a decade ago. Recently, advancements have been made in oncolytic therapy, with the promise of potentially transforming the melanoma treatment landscape. In these two 1.5-hour JADPRO Live classes on October 23, 2025, participants will have the opportunity to gain hands-on training experience in injecting different types of melanoma lesions. This training opportunity has been designed to complement the above activity, Oncolytic Therapy for Melanoma: An APP-focused Educational Curriculum.
Are you interested in participating in this exclusive training opportunity? If you are interested in the care of patients with melanoma and are planning to attend JADPRO Live 2025, please fill out this interest form. We will contact you individually about availability for these exclusive sessions.
The Integrita team brings a scalable, proven approach to healthcare advocacy. It’s about cutting through the clutter to get credible education and resources to the people who need them. It’s about building an engaged and informed community for underserved conditions through innovative methods. To learn more, see our Therapeutic Areas pages for our experience in scalable healthcare provider and patient advocacy initiatives. Harness the power of Integrita to fuel advocacy and make a difference today.